10月28日，康希诺生物盘中上涨6.1%，报29.2港元，成交额8151.65万港元。
消息面上，公司披露前三季度实现营业收入8.82亿元，同比增长27.40%；归母净利润1629.13万元，同比增长12.82%，业绩增长对股价形成支撑。
进一步看，第三季度单季营收3.32亿元，同比增长7.17%；前三季度非经常性损益收益6126.85万元，研发投入2.60亿元，占营收比重29.42%。此外，公司首批限制性股票归属81.13万股，并称减值及递延所得税资产减记合计影响净利3303万元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.